About Concentric Analgesic
Concentric Analgesic is a company based in San Francisco (United States) founded in 2014 by John Donovan and Craig Husfeld. Concentric Analgesic has raised $85.46 million across 4 funding rounds from investors including TD Securities, Oracle Investment Management and Venrock Capital Partners. Concentric Analgesic offers products and services including TRPV1 Agonist Prodrugs. Concentric Analgesic operates in a competitive market with competitors including Avidity Biosciences, Flexion Therapeutics, Univercells, Sutro Biopharma and Vividion Therapeutics, among others.
- Headquarter San Francisco, United States
- Founders John Donovan, Craig Husfeld
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website concentricanalgesics.com
- Social LinkedIn X
- Legal Name Concentric Analgesics, Inc.
- Total Equity Funding$85.46M (USD)
in 4 rounds
- Latest Funding Round$77.1M (USD), Series B
May 2019
- InvestorsTD Securities
& 3 more
Products & Services of Concentric Analgesic
Concentric Analgesic offers a comprehensive portfolio of products and services, including TRPV1 Agonist Prodrugs.
Provides long-lasting non-opioid pain relief via single local injection.
Funding Insights of Concentric Analgesic
Concentric Analgesic has successfully raised a total of $85.46M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $77.1 million completed in May 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $85.46M
- Total Rounds 4
- Last Round Series B — $77.1M
- First Round $8.36M
(Dec 2016)
- Investors Count 4
All 4 funding rounds of Concentric Analgesic with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2019 | $77.1M | Series B | – | Oracle Investment Management | |
| Nov 2018 | $20M | Debt – Conventional | – | – | – |
| Dec 2017 | $5.35M | Debt – Conventional | – | – | – |
| Dec 2016 | $8.36M | Series A | – | – | – |
4 investors in total: 4 institutional.
Investors in Concentric Analgesic
Concentric Analgesic has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include TD Securities, Oracle Investment Management and Venrock Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
VC & PE firm focused on healthcare sector | – | venrockcp.com | Palo Alto, United States | |
US private equity investments are managed by Kern Whelan Capital. | – | kernwhelan.com | Larkspur, United States | |
Research-driven investment firm focused on global health care and bioscience sectors. | 1993 | oraclepartners.com | Stamford, United States | |
Corporate finance advisory, mergers, acquisitions, and investment services are provided. | 1918 | cowen.com | New York, United States |
Investor details for Concentric Analgesic
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Concentric Analgesic
14 people are tracked at Concentric Analgesic (6 in leadership, 4 in board & advisors, 4 in team).
| Name | Role | Group |
|---|---|---|
John Donovan | Co-Founder & President | Leadership |
Craig Husfeld | Co-Founder | Leadership |
Frank J Bellizzi | CEO | Leadership |
Sam Teichman | VP, Head of Clinical Development | Leadership |
Nancy Wu | Head Of Clinical Operations | Leadership |
Monica Jenkins | Head Of Human Resources | Leadership |
Jonathan R. Lynch | Director | Board & advisors |
Sue Wollowitz | EVP, Pharmaceutical Operations | Board & advisors |
Thomas B. King | Director | Board & advisors |
Paul R. Carter | Director | Board & advisors |
Melissa Abel | Senior Commercial Strategy Advisor | Team |
Nancy Donahue | Commercial Advisor | Team |
Raymond Diokno | Bioanalytical Manager | Team |
Michelle Chung | Commercial Advisor | Team |
Complete people profiles for Concentric Analgesic
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Concentric Analgesic
3 dated milestones of Concentric Analgesic across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Concentric Analgesic is founded.
- Funding First funding round of $8.4M.
- Funding Latest funding round, Series B, of $77.1M.
Competitors of Concentric Analgesic
Concentric Analgesic operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Flexion Therapeutics, Univercells, Sutro Biopharma and Vividion Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| flexiontherapeutics.com | 2007 | Woburn, United States | $62M | 692 | Developer of therapies for the treatment of musculoskeletal disorders | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| straumann.com | 1954 | Basel, Switzerland | – | – | Dental implants and regenerative dentistry products are developed. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| judges.uk.com | 2002 | London, United Kingdom | – | 622 | Acquisition and development of scientific instrument businesses is conducted. | |
| savarapharma.com | 2008 | Austin, United States | $67.82M | 37 | Therapeutics for rare respiratory diseases are developed by Savara Pharma. |
Detailed competitors of Concentric Analgesic
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Concentric Analgesic
Complete news archive for Concentric Analgesic
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Concentric Analgesic
10 companies that operate in the same segment as Concentric Analgesic (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Concentric Analgesic
Concentric Analgesic was founded in 2014 and raised its 1st funding round 2 years after it was founded.
Concentric Analgesic is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Frank J Bellizzi is the current CEO of Concentric Analgesic.
Concentric Analgesic is a funded company, having raised a total of $85.46M across 4 funding rounds to date. The company's 1st funding round was a Series A of $8.36M, raised on Dec 2016.
Concentric Analgesic was founded in 2014 in San Francisco, United States, and operates in the biotechnology sector focused on analgesics. A platform for the discovery and development of pro-drugs is maintained, emphasizing non-opioid options that aim to reduce opioid consumption. The lead candidate, CA-008, a water-soluble prodrug converting to capsaicin as a TRPV1 agonist, is currently in phase II clinical trials.
Concentric Analgesic's top competitors include Sutro Biopharma, Flexion Therapeutics and Avidity Biosciences.
Concentric Analgesic offers TRPV1 Agonist Prodrugs.
Concentric Analgesic has 4 investors. Key investors include TD Securities, Oracle Investment Management, Venrock Capital Partners, and Kern Whelan Capital.
Concentric Analgesic operates through Concentric Analgesics, Inc..